Suzhou Immunofoco Biotechnology Co., Ltd
Clinical trials sponsored by Suzhou Immunofoco Biotechnology Co., Ltd, explained in plain language.
-
New hope for stomach cancer patients who have run out of options
Disease control Recruiting nowThis study tests a new drug called IMC002 for people with advanced stomach cancer that has not responded to at least two prior treatments. The goal is to see if IMC002 can slow tumor growth and help patients live longer compared to standard care. About 150 adults with a specific …
Phase: PHASE3 • Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd • Aim: Disease control
Last updated May 26, 2026 08:35 UTC
-
New cell therapy IMV102 targets Hard-to-Treat multiple myeloma in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called IMV102 in 30 people with multiple myeloma that has returned or not responded to at least three prior therapies. Participants receive a single infusion of IMV102, and researchers will monitor safety and how well it controls the c…
Phase: EARLY_PHASE1 • Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd • Aim: Disease control
Last updated May 26, 2026 08:32 UTC
-
New hope for tough lymphoma: experimental drug IMV101 enters human trials
Disease control Recruiting nowThis early-phase study tests a new drug called IMV101 in 30 adults with relapsed or refractory B-cell non-Hodgkin lymphoma, a type of blood cancer that has not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can s…
Phase: EARLY_PHASE1 • Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd • Aim: Disease control
Last updated May 18, 2026 12:03 UTC